- Atypical response to anti-PD-1 therapy followed by long-term survival in non-small cell lung cancer - case reports2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Advances in immunotherapy of melanoma2016 | Publication without faculty affiliation
- New trends in immunotherapy of melanoma2020 | First Faculty of Medicine
- Clinical dilemma of lung cancer treatment with anti-PD-1 therapy (nivolumab) in the discovery of rheumatological problems with joint swelling - case report2020 | First Faculty of Medicine
- Léčba checkpoint inhibitory anti-PD-1 u starších pacientů2019 | First Faculty of Medicine
- Radiotherapy and immunotherapy are irreplaceable in the treatment of cancer2020 | Faculty of Medicine in Hradec Králové
- Současné postavení monoterapie anti-PD-1 protilátkami v léčbě pokročilého melanomu2023 | First Faculty of Medicine
- Current treatment options for renal cell carcinoma and outlook2020 | Publication without faculty affiliation
- Adverse Effects of Modern Treatment of Malignant Melanoma and their Treatment/Management2014 | Faculty of Medicine in Hradec Králové
- A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade2023 | First Faculty of Medicine, Second Faculty of Medicine
- Complex treatment of melanoma2019 | First Faculty of Medicine
- Combination of nivolumab and relatlimab – a new option in the treatment of malignant melanoma2023 | Faculty of Medicine in Hradec Králové
- Pembrolizumab v terapii slizničního melanomu2016 | First Faculty of Medicine
- Imunoterapie a molekulárně cílená léčba u maligního melanomu2022 | First Faculty of Medicine
- Biologická léčba melanomu2016 | Publication without faculty affiliation
- News in immunotherapy of dMMR/MSI-H CRC2022 | Third Faculty of Medicine
- Pembrolizumab in combination with radiotherapy in a patient with generalized melanoma2020 | First Faculty of Medicine
- Immunotherapy of Renal Cell Carcinoma2017 | First Faculty of Medicine
- Advances in the treatment of metastatic melanoma2018 | First Faculty of Medicine
- European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 20232023 | Third Faculty of Medicine
- Melanom - současné a budoucí trendy léčby2017 | Publication without faculty affiliation
- Immunotherapy in treatment of lung cancer2016 | Publication without faculty affiliation
- Pembrolizumab in pretreated patient2018 | Faculty of Medicine in Hradec Králové
- Immunotherapy in lung cancer treatment2016 | Publication without faculty affiliation
- Gastrointestinal stromal tumour: advances in treatment2020 | Publication without faculty affiliation
- Efficacy and toxicity of combined immunochemotherapy in the treatment of patients with bronchogenic carcinoma with PD-L1 receptor expression < 1 % - case report2023 | First Faculty of Medicine
- Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines2022 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine
- Nivolumab in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- Nemelanomové kožní nádory - cemiplimab v léčbě pokročilého a metastazujícího kožního skvamózního karcinomu2021 | First Faculty of Medicine
- Advances in Immunotherapy of Malignant Melanoma2017 | Publication without faculty affiliation